InnoCare Optoelectronics (6861) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024, was NT$1,642,421 thousand, up 13% year-over-year from NT$1,451,984 thousand.

• Net income for the same period was NT$104,655 thousand, down 7% from NT$112,309 thousand year-over-year.

• Gross margin for the nine months was 27%, slightly down from 28% in the prior year.

• The company remains focused on X-ray flat panel detector components and modules for the medical sector.

Financial highlights

• Operating income for the nine months was NT$95,928 thousand, a decrease from NT$128,436 thousand year-over-year.

• Basic EPS for the nine months was NT$2.52, compared to NT$2.77 in the prior year.

• Cash and cash equivalents at September 30, 2024, were NT$734,886 thousand, up from NT$690,446 thousand a year earlier.

• Total assets increased to NT$2,449,354 thousand from NT$2,266,814 thousand year-over-year.

• Short-term borrowings decreased to NT$80,000 thousand from NT$100,000 thousand year-over-year.

Outlook and guidance

• The company continues to invest in long-term strategic equity investments and expects no significant impact from new IFRS standards.

• Plans to relocate to a new facility in March 2025, with a five-year lease valued at NT$105,255 thousand.